EBITDA: Income before interest, taxes, depreciation and amortization.
BridgeBio Oncology Therapeutics, Inc (BBOT) had EBITDA of $-45.99M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-42.11M |
|
-- |
|
-- |
|
$46.18M |
|
$-46.18M |
|
$4.07M |
|
$-42.11M |
|
$-42.11M |
|
$-42.11M |
|
$-42.11M |
|
$-42.11M |
|
$-42.11M |
|
$-46.18M |
|
|
EBITDA |
$-45.99M |
80.03M |
|
80.03M |
|
$-526.11 |
|
$-526.11 |
|
| Balance Sheet Financials | |
$266.50M |
|
$0.94M |
|
$151.14M |
|
$417.65M |
|
$43.26M |
|
-- |
|
$2.11M |
|
$45.37M |
|
$372.28M |
|
$372.28M |
|
$372.28M |
|
80.09M |
|
| Cash Flow Statement Financials | |
$-35.92M |
|
$-285.41M |
|
$0.29M |
|
$373.82M |
|
$52.79M |
|
$-321.03M |
|
$3.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.16 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.94M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.31% |
|
-11.31% |
|
-10.08% |
|
-11.31% |
|
$4.65 |
|
$-0.45 |
|
$-0.45 |
|